Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biopharmaceutical company focused on organ-selective medicines for respiratory and neurologic conditions, and the TBPH news feed highlights the company’s ongoing clinical, regulatory, commercial, and corporate developments. Company communications emphasize its role in the development of YUPELRI (revefenacin) inhalation solution, an FDA-approved once-daily nebulized LAMA for the maintenance treatment of COPD, and its late-stage investigational program with ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
News items for Theravance Biopharma commonly cover financial results and corporate updates, including quarterly earnings releases, collaboration revenue from YUPELRI, and commentary on operating discipline and capital allocation. Investors can also follow clinical development milestones, such as completion of enrollment in the Phase 3 CYPRESS study of ampreloxetine, the conclusion of open-label study periods, and anticipated timelines for topline data.
The TBPH news stream features scientific and medical conference activity, including platform and poster presentations on ampreloxetine at meetings like the International Symposium on the Autonomic Nervous System, as well as presentations and data on YUPELRI at respiratory congresses. In addition, Theravance Biopharma announces disease education initiatives such as the "Power in the Periphery" campaign and other efforts aimed at increasing awareness and understanding of nOH due to MSA among healthcare professionals.
Investors tracking TBPH can also see announcements about investor conferences and KOL events, where management and external experts discuss unmet medical needs in MSA-related nOH, review the ampreloxetine clinical program, and outline commercial strategies. For those following Theravance Biopharma stock, this news page provides a consolidated view of the company’s operational progress, scientific outreach, and key catalysts related to its respiratory and neurologic portfolios.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) will present four ampreloxetine presentations at the 36th International Symposium on the Autonomic Nervous System, Nov 5-8, 2025, in Clearwater Beach, FL.
One platform presentation on precision therapy in multiple system atrophy (MSA) will be given on Nov 8, 2025 at 8:30 am ET. Three posters on supine hypertension, retention strategies, and enrollment strategies will be presented on Nov 6, 2025 at 7:00-8:30 pm ET. Topline results from the ongoing Phase 3 CYPRESS study are anticipated in Q1 2026.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) launched “Power in the Periphery,” a disease education campaign for healthcare professionals to raise awareness of neurogenic orthostatic hypotension (nOH) in Multiple System Atrophy (MSA).
The initiative was introduced at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Honolulu, October 5–9, 2025, and aims to deepen scientific understanding of nOH pathophysiology in MSA and improve clinician engagement. nOH symptoms include lightheadedness, fainting, fatigue, blurry vision, weakness, concentration problems, and head/neck pain. Theravance directs clinicians to www.nOHUncovered.com for educational resources.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
